Use of pathological response versus RECIST assessment in predicting relapse-free survival following neoadjuvant immunotherapy for hepatocellular carcinoma. Expanded biomarker analysis of an ...

Hepatocellular carcinoma is a leading cause of cancer-related death globally. The treatment of hepatocellular carcinoma is complex, with diverse therapeutic approaches and their combinations available ...

A new study in the Journal of Interferon & Cytokine Research (JICR) showed that a specific retinoic acid-inducible gene I ...

Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...

Hepatocellular carcinoma (HCC) is one of the deadliest cancers globally, with increasing incidence and mortality rates.

Hepatocellular carcinoma (HCC) is one of the deadliest malignant tumors in the world, and its incidence and mortality have ...

On 12 Feb 2025, Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from the U.S. Food and Drug Administration (FDA) to initiate an ...

Announcing a new publication for Acta Materia Medica journal. Icaritin (ICA) is a prenylflavonoid natural product extracted from plants of the Epimedium genus. The approval of ICA softgel capsules as ...